Gemigliptin, formerly known as LC15-0444, is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor was approved in South Korea as an orally bioavailable anti-hyperglycemic agent (anti-diabetic drug). Gemigliptin dose-dependently inhibited methylglyoxal-modified AGE-bovine serum albumin (BSA) formation (IC50=11.69 mM). AGE-collagen cross-linking assays showed that gemigliptin had a potent inhibitory effect (IC50=1.39 mM) on AGE-BSA cross-links to rat tail tendon collagen, and its activity was stronger than aminoguanidine (IC50=26.4 mM). References: Jung E, Kim J, Kim CS, Kim SH, Cho MH. Gemigliptin, a dipeptidyl peptidase-4 inhibitor, inhibits retinal pericyte injury in db/db mice and retinal neovascularization in mice with ischemic retinopathy. Biochim Biophys Acta. 2015 Dec;1852(12):2618-29. doi: 10.1016/j.bbadis.2015.09.010. Epub 2015 Sep 21. PubMed PMID: 26391252.

纯度：≥98%

CAS：911637-19-9